Vaccines

La E, Sweeney C, Davenport E, Bunniran S. Work loss associated with adult vaccinations in pharmacy and healthcare professional office settings in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S138. doi: 10.1016/j.jval.2024.03.738


OBJECTIVES Value of vaccination analyses often use assumptions or dated estimates from published literature for work loss associated with vaccine administration. This study evaluates work loss among adults recently vaccinated in pharmacies or healthcare professional (HCP) offices in the United States (US).

Molnar D, La EM, Verelst F, Poston S, Graham J, Van Bellinghen LA, Curran D. Public health impact of the adjuvanted RSVPreF3 vaccine for respiratory syncytial virus prevention among older adults in the United States. Infect Dis Ther. 2024 Apr;13(4):827-44. doi: 10.1007/s40121-024-00939-w


INTRODUCTION: Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract disease in older adults, resulting in substantial morbidity and mortality.

La E, Verelst F, Curran D, Poston S, Graham J, Molnar D. Public health impact and cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults AGED ≥60 years in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.


Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled impact of adjuvanted RSVPREF3 vaccination on RSV-related health outcomes in adults aged 50-59 years with cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.


BACKGROUND: Cardiopulmonary disease is associated with an increased risk of severe respiratory syncytial virus (RSV) disease in adults. This study estimated the potential public health impact of adjuvanted RSVPreF3 vaccination in adults 50-59 years of age (YOA) with select cardiopulmonary diseases in the United States (US).

Singer D, La E, Graham J, Grace M, Poston S, Molnar D. Modeled burden of RSV in adults aged 50-59 years with chronic cardiopulmonary diseases in the United States. Poster presented at the 8th ReSViNET Conference 2024; February 13, 2024. Mumbai, India.


BACKGROUND: Adults with chronic cardiopulmonary conditions are at increased risk of severe respiratory syncytial virus (RSV) disease. This study estimated the burden of RSV in adults 50-59 years of age (YOA) with chronic cardiopulmonary diseases in the United States (US).

Herrera-Restrepo O, Bunniran S, Mond T, Davenport E, Wang J, Sweeney C, Marshall GS. United States physicians' knowledge, attitudes, and practices regarding meningococcal vaccination for healthy adolescents and young adults. J Adolesc Health. 2024 Jun;74(6):1131-8. doi: 10.1016/j.jadohealth.2023.11.394


Layton JB, Peetluk L, Wong HL, Jiao Y, Djibo DA, Bui C, Lloyd PC, Gruber JF, Miller M, Ogilvie RP, Deng J, Parambi R, Song J, Weatherby LB, Lo AC, Matuska K, Wernecke M, Clarke TC, Cho S, Bell EJ, Seeger JD, Yang GW, Illei D, Forshee RA, Anderson SA, McMahill-Walraven CN, Chillarige Y, Amend KL, Anthony M, Shoaibi A. Effectiveness of monovalent COVID-19 booster/additional vaccine doses in the United States. Vaccine-X. 2024 Jan;16:100447. doi: 10.1016/j.jvacx.2024.100447


BACKGROUND: Monovalent booster/additional doses of COVID-19 vaccines were first authorized in August 2021 in the United States. We evaluated the real-world effectiveness of receipt of a monovalent booster/additional dose of COVID-19 vaccine compared with receiving a primary vaccine series without a booster/additional dose.

Shamarina D, Sluga-O'Callaghan M, Kassianos G, Marijam A, Dave V, Davenport E, Andani A, Curran D, Dewda P, Steffen R. Knowledge, attitudes, and practices of European healthcare professionals towards hepatitis A and hepatitis B vaccination in at-risk adults. Vaccines (Basel). 2023 Oct 26;11(1645):1-19. doi: 10.3390/vaccines11111645


Herrera-Restrepo O, Sweeney C, Mond T, Davenport E, Wang J, Marshall GS. Nurse practitioners' and physician assistants' knowledge, attitudes, and practices regarding meningococcal vaccination for healthy adolescents and young adults in the United States. J Nurse Pract. 2024 Jan;20(1):104793. doi: 10.1016/j.nurpra.2023.104793


La EM, Bunniran S, Garbinsky D, Reynolds M, Schwab P, Poston S, Harrington L. Respiratory syncytial virus knowledge, attitudes, and perceptions among adults in the United States. Hum Vaccin Immunother. 2024 Dec 31;20(1):2303796. doi: 10.1080/21645515.2024.2303796


Subscribe to Vaccines

How Can We Help You?